
    
      HBeAg positive patients with HBV DNA load â‰¥1000copies/ml after 6 months of peginterferon
      alpha 2a treatment will be enrolled randomized into two groups, in intervention group,
      patients will receive entecavir combine with peginterferon alpha 2a(PEG-IFN a-2a) treatment
      for 48 weeks and follow 24 weeks. Patients in control group will be continue treated with
      PEG-IFN a-2a for 48 weeks and followed 24 weeks. Serum HBV DNA load, HBsAg/anti-HBs level,
      HBeAg/anti-HBe will be tested at enrollment and every 3 months during the treatment course.
      Parameters of Liver and kidney function, and liver ultrasound examination will be tested with
      intervals 1-3 months. The efficacies of the combined therapy were evaluated by the rates of
      HBeAg seroconversion and HBsAg loss after 48 weeks of combined therapy, compared with control
      group.
    
  